FDA Adverse Event Injury Summary report: N

DEPUY ASR XL FEM IMP SIZE 46

MDR report key: 3212174 · Received July 8, 2013

Report

Report Number
1818910-2013-20710
Event Type
Injury
Date Received
July 8, 2013
Date of Event
March 3, 2009
Report Date
June 21, 2013
Manufacturer
DEPUY INTERNATIONAL LTD. 8010379
Product Code
KXA
Removal / Correction Number
Z-1749/1816-2011
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
US
Reporter Occupation
PATIENT

Narratives

Additional Manufacturer Narrative · 1

NO 510(K) NUMBER PROVIDED BECAUSE THIS IMPLANT IS SOLD INTERNATIONALLY WITH DIFFERENT INDICATIONS FOR USE; IT IS CURRENTLY SOLD IN THE US UNDER A DIFFERENT PART NUMBER. THE CORRECTION/REMOVAL REPORTING NUMBER LISTED APPLIES TO THE CORRESPONDING PRODUCT CODE SOLD DOMESTICALLY. THE ASR PLATFORM WAS VOLUNTARILY RECALLED FROM THE MARKET IN AUGUST 2010, AND THE ASR PRODUCT CODES ARE NOW CONSIDERED INACTIVE. FURTHER INVESTIGATION OF THIS INDIVIDUAL INCIDENT WILL NOT BE UNDERTAKEN, AS THERE IS AN ONGOING INVESTIGATION REGARDING THE ROOT CAUSE(S) AND/OR CORRECTIVE ACTIONS. (B)(4). DEPUY CONSIDERS THE INVESTIGATION CLOSED AT THIS TIME. SHOULD THE PRODUCT AND/OR ADDITIONAL INFORMATION BE RECEIVED, THE INVESTIGATION WILL BE RE-OPENED.

Additional Manufacturer Narrative · 1

IF INFORMATION IS OBTAINED THAT WAS NOT AVAILABLE FOR THE INITIAL MEDWATCH, A FOLLOW-UP MEDWATCH WILL BE FILED AS APPROPRIATE.

Description of Event or Problem · 1

ASR REVISION; ASR XL - RIGHT; REASON(S) FOR REVISION: COMPONENT LOOSENING - ACETABULAR CUP. UPDATE RECEIVED: (B)(4) 2013 - ADDED FURTHER REVISION REASONS: PAIN, COMPONENT MALALIGNMENT, DISLOCATION, ALVAL / SOFT TISSUE REACTION AND INFECTION (POSITIVE CULTURE).

Description of Event or Problem · 1

ASR REVISION;ASR XL - RIGHT;REASON(S) FOR REVISION: COMPONENT LOOSENING - ACETABULAR CUP.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
311720 DEPUY ASR XL FEM IMP SIZE 46 FEMORAL HEAD KXA DEPUY INTERNATIONAL LTD. 8010379 2072960

Patients

Seq Age Sex Outcome Treatment
1 Required Intervention